Skip to main content

HLB Pharmaceutical Co., Ltd (047920.KQ)

KOE Healthcare Drug Manufacturers - Specialty & GenericView data quality →
42.6Fair

ValueMarkers Composite Index

Top 9%#40,864 of 44,714

DCF data not available

Piotroski
5/9
Neutral
Beneish
-1.54
High Risk
Altman
9.48
Safe
DCF Value
-
N/A
ROIC
0.7%
Low
P/E
134.4
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

HLB Pharmaceutical Co., Ltd (047920.KQ) — VMCI valuation read

HLB Pharmaceutical Co., Ltd (047920.KQ) carries a VMCI composite of 43/100, 7 points below the Healthcare sector median of 50. Among mid-cap names, that gap places 047920.KQ in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The 047920.KQ insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads 047920.KQ trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -2.1x leaves covenant headroom, the line to track on HLB Pharmaceutical Co., Ltd's next 10-Q.

047920.KQ fell 0.3% over the trailing 7 days, with a +7.4% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 047920.KQ’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.